Develop Safe, Targeted In Vivo Delivery of RNA, Viral or Gene-Editing Payloads with Clarity in Regulations & Translational Strategy

June 03-05, 2025 | Boston, MA

2025 Agenda
Register
Become a Partner

Join the Cell & Gene Community and Advance the Next Frontier of In Vivo Approaches from Research to Clinic

Welcome to the 4th In Vivo Cell Engineering & Gene Editing Summit, the only in vivo dedicated event designed to progress cell and gene therapies to the next frontier.

This summit provides you with exclusive insights into pioneering IND enabling and clinical data, delivery technologies and effective clinical trial designs. Alongside all of this, our speaker faculty will explore regulatory and inter-governmental requirements to accelerate your clinical pipeline.

This year's experts include C-suite executives, VPs and Directors from Myeloid Therapeutics, Ensoma, Capstan Therapeutics, Editas Medicines, AbbVie, Intellia Therapeutics, Umoja BiopharmaΒ and many more!

Biotech and pharma companies are shifting from ex vivo to in vivo therapies due to their improved efficiency, accessibility and cost-effectiveness. With this in mind, this event is a must-attend for those looking to pioneer in this evolving field.

 

Can you afford to miss out?

Access the agenda for the 4th In Vivo Cell Engineering & Gene Editing Summit
View the Agenda

"In vivo genetic medicines are the future, so having a forum for leaders in the field to explore ways to navigate development to meet the needs of patients is very exciting"
Nicolas Boyle, Chief Executive Officer, Abintus Bio

World-Class Speaker Faculty Includes:

CΓ©cile Bauche

Founder & Chief Scientific Officer

Alaya.bio

Dana foss

CEO

Editpep

Daniel Getts

Chief Executive Officer & Co-Founder

Myeloid Therapeutics

Gilmore O’Neill

President & Chief Executive Officer

Editas Medicine

John Rossi, VP & Head of Translational Medicine at Capstan Therapeutics

John Rossi

Vice President & Head of Translational Medicine

Capstan Therapeutics

Maurits Geerlings

Co-Founder, President & CEO

NanoCell Therapeutics

View the Speaker Faculty
See Who Else is Attending

Showcase Your Research!

As an attendee, you will also have the opportunity to share your research in our dedicated Poster Session. This will give you the opportunity to demonstrate your thought leadership and attract the attention of industry stakeholders.

Time is running out... submissions close Monday, May 19th.

Find Out More

"The In Vivo Cell Engineering & Gene Editing Summit is a tremendous opportunity to engage with leaders in the field and discuss the latest advances"
Colin Exline, Head of Gene Editing, Primera Therapeutics

Latest Industry News

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2β€―Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Sarepta’s DMD Gene Therapy Elevidys Demonstrates Manageable Safety Across 5-Year Timespan

FDA Clears IND Application for VERVE-102 Gene Therapy for HeFH

Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14

Eli Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy

Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing to Further Advance Ocular Gene Therapy Programs

View the Full Agenda for More Information on:

        • 21+ In Vivo C-Suite Executives, VPs and Directors
        • 20+ Exclusive Sessions
        • 2 Interactive Deep-Dive Workshops
        • 8+ Hours of Industry Networking

Β  Β  Β  Β  Β  Β  Β  Β  Β  & Much More!

Explore Here
Access the agenda for the 4th In Vivo Cell Engineering & Gene Editing Summit
2025 Agenda
Register
Become a Partner